

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Reginald F. Frye, Pharm.D., Ph.D.		POSITION TITLE Associate Professor	
eRA COMMONS USER NAME fryerf			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Oglethorpe University, Atlanta, GA.	B.S.	1986	Biology
Mercer University, Atlanta, GA.	Pharm.D.	1990	Clinical Pharmacy
University of Pittsburgh, Pittsburgh, PA.	Ph.D.	1995	Clinical Pharmaceutical Science

A. Positions and Honors.**Positions and Employment**

- 1990 - 1991 Clinical Pharmacokinetics Fellow and Clinical Instructor, School of Pharmacy, University of North Carolina, Chapel Hill, NC.
- 1991 - 1993 American Society of Health Systems Pharmacists Fellow in Clinical Pharmacokinetics, Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA.
- 1991-1995 Graduate Student, Department of Pharmacy and Therapeutics, School of Pharmacy, and Member, Center for Clinical Pharmacology, School of Medicine, University of Pittsburgh, Pittsburgh, PA.
- 1995-2002 Assistant Professor, Department of Pharmaceutical Sciences, School of Pharmacy, and Member, Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA.
- 1998-2003 Director, Clinical Pharmacology Analytical Facility, Center for Clinical Pharmacology.
- 2001-2003 Associate Member, Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh.
- 2002-2003 Associate Professor with tenure, Department of Pharmaceutical Sciences, School of Pharmacy, and Member, Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA.
- 2003-present Associate Professor with tenure, Departments of Pharmacy Practice and Pharmaceutics Associate Director, Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL.

Professional Activities

NIH/NIMH – Special Emphasis Panel (ZMH1-CRB-B-01) member, December 2001.

NIH/NCCAM – Special Emphasis Panel (ZAT1 CP-10) member, September 2003.

NIH – Center for Scientific Review Special Emphasis Panel (ZRG1 RPHB-B (05): Cancer Treatment), Ad hoc reviewer. November 2004, July 2005.

B. Selected peer-reviewed publications (in chronological order).

(selected from 72 peer reviewed manuscripts and 10 book chapters):

- Frye RF**, Branch RA. Effect of chronic disulfiram administration on activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. *Br J Clin Pharmacol* 2002; 53:155-162.
- Islam M, **Frye RF**, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. Differential Effect of Interferon Alfa-2b (IFNa2b) on the Cytochrome P450 Enzyme System: A Potential Basis of IFN Toxicity and its Modulation by Other Drugs. *Clinical Cancer Research* 2002;8(8): 2480-7.
- Alkharfy KM, **Frye RF**. Sensitive HPLC-fluorescence method for the determination of estradiol-3 and 17 glucuronides in rat and human liver microsomes. *J Chromatogr B Biomed Sci Appl* 2002;774:33-38.
- Solai LK, Pollock BG, Mulsant BH, **Frye RF**, Miller M, Sweet R, Kirshner M, Sorisio D, Begley A, and Reynolds CF. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. *J Clin Psychopharmacol* 2002; 22: 481-6.

- Frye RF**, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF- α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. *J Card Failure* 2002; 8(5):315-9.
- Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, **Frye RF**. Application of semisimultaneous midazolam administration for hepatic and intestinal CYP3A phenotyping. *Clin Pharmacol Ther* 2002;72:718-28.
- Nolin TD, **Frye RF**. Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2003;783:265-271.
- Lee CR, Pieper JA, **Frye RF**, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, Flurbiprofen and Losartan as Probes of CYP2C9 Activity in Humans. *J Clin Pharmacol* 2003;43:84-91.
- Chalon SA, Desager JP, DeSante KA, **Frye RF**, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. *Clin Pharmacol Ther*. 2003 Mar;73(3):178-191.
- Lee CR, Pieper JA, **Frye RF**, Hinderliter AL, Blaisdell JA, Goldstein JA. Flurbiprofen Metabolism in CYP2C9*1 Heterozygotes. *Eur J Clin Pharmacol* 2003; 58(12):791-4.
- Carcillo JA, Doughty L, Kofos D, **Frye RF**, Kaplan SS, Sasser H, Burckart GJ. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. *Intensive Care Med*. 2003; Jun;29(6):980-4.
- Carcillo JA, Adedoyin A, Burckart GJ, **Frye RF**, Venkataramanan R, Knoll C, Thummel K, Roskos L, Wilson JW, Sereika S, Romkes M, Bebia Z, Branch RA. Coordinated Intrahepatic and Extrahepatic Regulation of CYP2D6 in Health and Following Liver Transplantation. *Clin Pharmacol Ther* 2003; 73: 456-67.
- Nolin TD, Gastonguay MR, Bies RR, Matzke GR, **Frye RF**. Impaired 6-Hydroxychlorzoxazone elimination in patients with kidney disease: implication for CYP2E1 pharmacogenetic studies. *Clin Pharmacol Ther* 2003;74(6);555-568.
- Hruska MW, **Frye RF**. Simplified method for determination of rosiglitazone in human plasma. *J Chromatogr B* 2004;803:317-20.
- Komoroski BJ, Zhang S, Cai H, Hutzler JM, **Frye R**, Tracy TS, Strom SC, Lehmann T, Ang, Yan CY, Cui Y, Venkataramanan R. Induction and inhibition of cytochromes P450 by the St. John's Wort constituent hyperforin in human hepatocyte cultures. *Drug Metab Dispos* 2004;32(5):512-8.
- Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, **Frye RF**, Zemaitis MA. The effect of isoniazid on CYP2E1 and CYP4A mediated hydroxylation of arachidonic acid in the rat liver and kidney. *Drug Metab Dispos* 2004;32(7):727-33.
- Hruska MW, **Frye RF**. Determination of trimethoprim in low-volume human plasma by liquid chromatography. *J Chromatogr B* 2004; 807(2):301-5.
- Frye RF**, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St. John's Wort on imatinib mesylate pharmacokinetics. *Clin Pharmacol Ther* 2004;76:323-9.
- Hruska MW, **Frye RF**, Langaee TY. A Pyrosequencing Method for Genotyping Cytochrome P450 2C8 and 2C9 Enzymes. *Clin Chem* 2004; 50(12):2392-5.
- Bebia Z, Buch SC, Wilson JW, **Frye RF**, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA. Bio-equivalence revisited: Influence of age and sex on CYP enzymes. *Clin Pharmacol Ther* 2004;76:618-27.
- Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, **Frye RF**. The Effect of Trimethoprim on CYP2C8 Mediated Rosiglitazone Metabolism in Human Liver Microsomes and Healthy Subjects. *Br J Clin Pharmacol* 2005;59(1):70-9.
- Harbrecht BG, **Frye RF**, Zenati MS, Branch RA, Peitzman AB. Cytochrome P-450 activity is differentially altered in severely injured patients. *Crit Care Med*. 2005 Mar;33(3):541-6.
- Liu S, **Frye RF**, Branch RA, Venkataramanan R, Fung J, Burckart GJ. Changes in CYP450 enzyme activity over time following liver transplantation. *J Clin Pharmacol* 2005 Jun;45(6):666-73.
- Haas CE, Brazeau D, Cloen D, Booker BM, Frerichs V, Zaranek C, **Frye RF**, Kufel T. Cytochrome P-450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. *Eur J Clin Pharmacol* 2005; Sep;61(8):583-93.